MA-CYTOTRONICS
10.7.2024 08:01:25 CEST | Business Wire | Press release
CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, introduced its high-throughput Pixel™ Octo system at the International Society for Stem Cell Research (ISSCR 2024) in Hamburg, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709748131/en/
CytoTronics is launching its high-throughput Pixel™ Octo system (right) at the International Society for Stem Cell Research (ISSCR 2024) in Hamburg, Germany. The ISSCR conference also marks the European reveal of CytoTronics’ product portfolio, including the entry-level Pixel Primo (left), a single plate reader that brings accessibility to researchers. (Photo: Business Wire)
This new addition to the Pixel lineup integrates the company’s semiconductor-to-live-cell interface in an environmental controlled benchtop system to deliver live cell measurements for up to eight 96-well Pixel plates simultaneously. When paired with laboratory robotic automation, the Pixel Octo offers full scalability in high-throughput cell biology applications. The ISSCR conference also marks the European reveal of CytoTronics’ product portfolio, including the entry-level Pixel Primo, a single plate reader that brings accessibility to researchers for under US$30,000.
Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, and more while generating electrical ‘images’ with single-cell spatial resolution. It dramatically accelerates the scale at which cell biology applications can be executed, and the breadth and depth of live-cell insights obtained. Pixel enables new applications for endothelial and epithelial cells, cancer cell biology, mechanism of action/toxicology, stem cell biology, cardiac function, and neural function.
Scale up of in vitro cell-based assays is challenging. Traditionally, these screening assays at high scale use hundreds of 96- or 384- well plates to measure simple cellular properties (e.g., "live or dead" screens) to select the most prospective 'hits' of interest, which are then 'scaled down' to verify key effects on cellular functions. Pixel gives researchers a highly sophisticated tool to start key investigations first, get the functional phenotypic assets they cannot get through imaging and other basic techniques, and easily scale these newly developed assays to high-throughput workflows.
The Pixel plate, a proprietary 96-well electronic microplate embedded with custom-designed semiconductor microchips at the base of each well, is at the core of CytoTronics’ Pixel platform. Cells grow in culture media on top of a microarray containing over 100,000 nanoscale electrode-based sensors, enabling thousands of measurements to be taken per well on a single-cell level, on any cell type, spheroid, or 3D organoid system.
In-vitro cell-based assays can initially be developed on Pixel Primo, a single plate reader that can be placed in any standard cell culture incubator. Cell biologists can then scale those assays 8× on Pixel Octo, a self-contained benchtop system complete with a dedicated incubator to regulate temperature, CO2, humidity, and oxygen. Labs can integrate Pixel Octo with industry standard robotic and liquid handling platforms, and multiple systems can be run in parallel for high-throughput applications. Availability of 384-well Pixel plates later in 2024 raises the scalability bar significantly, adding capability to screen tens of thousands of wells simultaneously.
“There’s a tremendous unmet need in cell biology discovery applications to measure the unique cell parameters that Pixel captures. It unlocks new applications and reveals data that scientists haven’t been able to study before,” said Jeffrey Abbott, Ph.D., Co-Founder and CEO of CytoTronics. “Pixel Octo takes the power of our unique semiconductor-to-biology interface from assay development in a single plate and unleashes it for high-throughput applications, from exploratory assays on a single Pixel plate to fully validated cell-based applications running at industrial scale.”
“Our early access program for the Pixel Primo kicked off in February and already has 20 global partners spanning biotech, pharmaceutical, academic, cell and organoid providers, and computational biology organizations who are very quickly gaining traction on their applications,” said Duane Sword, Co-Founder and CBO at CytoTronics. “Pixel Octo was designed with scalability in mind and provides cell monitoring and data collection at unprecedented scale. Importantly, Pixel is complementary with imaging and HCS (high content screening) techniques and designed to integrate with standard automation workflows. Pixel is rich with information on biology never seen before, let alone at scale. Hence, we have designed the system with a cloud-centric architecture spanning measurement design, execution, analysis and reporting.”
Through the CytoTronics early access program, customers receive a Pixel Primo, 96-well Pixel plates and Pixel Pro, a cloud-based control and interactive analysis software. A starting list price of under $30K (USD) makes it easy for labs to evaluate Pixel as the next frontier of their cell biology research programs.
To learn more about Pixel or enroll in the early access program, visit www.cytotronics.com. You can also visit CytoTronics at ISSCR in Hall H booth #1016 and attend our talks on “Electrical imaging: live cell characterization from stem cell biology to phenotypic disease models”, presented by Shalaka Chitale, CytoTronics’ Director of Biology, Thursday July 11 at 9:10am - 9:20am and Friday July 12 at 6:00pm – 6:30pm.
About Pixel
CytoTronics’ breakthrough semiconductor-to-live-cell interface powered by microchips enables thousands of multi-modal readouts on any cell type or organoid system. Live cell function is monitored on a Pixel plate, a proprietary 96- or 384-well microplate embedded with microchips at the base of each well. Cells grow in culture media on top of a microarray containing over 100,000 nanoscale electrode-based sensors, allowing thousands of measurements to be taken per well. Pixel Primo and Octo offer simultaneous monitoring of cells across all wells of either a single Pixel plate or eight at the same time. Cloud-based Pixel Pro software enables applications across multiple cell types and organoids with cloud-based control and interactive analysis of the data-rich, live cell measurements collected.
About CytoTronics
At CytoTronics, we are transforming cell biology discovery with our high-throughput, semiconductor-based platforms. Our Pixel systems provide live cell insights with single-cell resolution across all cell types. By seamlessly integrating semiconductors with conventional microplates, Pixel unlocks multi-modal electrical, electrochemical, and electrophysiological capabilities, delivering an unprecedented scope of data collection and scale-up for cell biology research, drug development, and pharmaceutical manufacturing applications. Established as a spin-off from Harvard University in 2021, we are headquartered in Boston, Massachusetts. Learn more at www.cytotronics.com or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709748131/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
